BridgeBio Pharma, Inc. (BBIO) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$67.35

From 52W high−24.65%

Volume2.05M

Market cap$13.28B

P/E (TTM)—

P/S (TTM)18.6x

Div yield—

Key dataOct 19, 2026

Open

$67.35

From 52W high

−24.65%

Volume

2.05M

Market cap

$13.28B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−24.6x

P/E (TTM)

—

RSI (14)

49.7

MomentumView details →

1D Return

+2.33%

YTD Return

−11.18%

SummaryUpdated Jun 1, 2026

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biotechnology company founded in 2015 and headquartered in Palo Alto, California. The company went public in June 2019 and focuses on discovering, developing, and delivering medicines for genetic diseases. BridgeBio operates with a unique decentralized model, creating subsidiary companies around specific therapeutic programs while maintaining a centralized platform for shared resources and expertise. The company has achieved its first major commercial success with the FDA approval and launch of Attruby (acoramidis) in 2024 for the treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM), marking a significant milestone in its evolution from a pure development-stage company to a commercial enterprise.

Ask drillr about BridgeBio Pharma, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−24.6x

EV/Sales

21.1x

P/S (TTM)

18.6x

P/B (TTM)

−5.3x

ProfitabilityView details →

Gross Margin

93.35%

Net Margin

−97.64%

EBITDA Margin

−85.72%

ROE (TTM)

27.68%

ROA (TTM)

−57.20%

Asset Turnover

0.55x

GrowthView details →

Revenue YoY

+202.39%

EPS YoY

+12.47%

FCF YoY

+34.10%

Revenue CAGR 3Y

+86.30%

EPS CAGR 3Y

−31.60%

EBITDA YoY

+5.02%

MomentumView details →

1D Return

+2.33%

YTD Return

−11.18%

1Y Return

+20.76%

RSI (14)

49.7

vs 50D SMA

−6.44%

vs 200D SMA

−6.98%

Capital & dividendView details →

Debt/Equity

−0.99x

Current Ratio

1.23x

Quick Ratio

1.17x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.78

EPS Surprise

−35.52%

Beats (12Q)

2/12

Next Q EPS Est

−$0.47

Avg Surprise (4Q)

−24.20%

Rev Surprise

10.31%

Financials snapshotView financials →

Revenue (TTM)

713.07M

Net Income (TTM)

−696.24M

Op. CF (TTM)

−434.37M

Next earningsOct 28, 2026 →

Latest newsMore news →

The FDA accepted for priority review BridgeBio's New Drug Application for oral infigratinib for children with achondroplasia, with a PDUFA target action date of February 4, 2027.13d ago

Similar companies

迈威生物-U688062.SH Jazz Pharmaceuticals plcJAZZ 生物股份600201.SH Halozyme Therapeutics, Inc.HALO Metis Techbio-p07666.HK Summit Therapeutics Inc.SMMT Find similar companies →

Latest newsMore news →

BridgeBio Pharma announced that it will present one oral presentation, three rapid-fire oral presentations and six poster presentations on acoramidis at the HFSA Annual Scientific Meeting 2026.13d ago The FDA accepted for priority review BridgeBio's New Drug Application for oral infigratinib for children with achondroplasia, with a PDUFA target action date of February 4, 2027.13d ago BridgeBio Pharma announced new exploratory results from its Phase 3 PROPEL 3 trial of oral Infigratinib in children with achondroplasia, showing benefits beyond growth, and plans a potential U.S. launch in mid-2027.40d ago